Arizona 2023 Regular Session

Arizona House Bill HB2723 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	REFERENCE TITLE: sickle cell disease; annual review State of Arizona House of Representatives Fifty-sixth Legislature First Regular Session 2023 HB 2723 Introduced by Representatives Marshall: Diaz, Gillette, Hendrix, Smith An Act amending title 36, chapter 29, article 1, Arizona Revised Statutes, by adding section 36-2903.14; relating to the Arizona health care cost containment system. (TEXT OF BILL BEGINS ON NEXT PAGE)
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9	REFERENCE TITLE: sickle cell disease; annual review
10	10	State of Arizona House of Representatives Fifty-sixth Legislature First Regular Session 2023
11	11	HB 2723
12	12	Introduced by Representatives Marshall: Diaz, Gillette, Hendrix, Smith
13	13
14	14	REFERENCE TITLE: sickle cell disease; annual review
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24	State of Arizona
25	25
26	26	House of Representatives
27	27
28	28	Fifty-sixth Legislature
29	29
30	30	First Regular Session
31	31
32	32	2023
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40	HB 2723
41	41
42	42
43	43
44	44	Introduced by
45	45
46	46	Representatives Marshall: Diaz, Gillette, Hendrix, Smith
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64	An Act
65	65
66	66
67	67
68	68	amending title 36, chapter 29, article 1, Arizona Revised Statutes, by adding section 36-2903.14; relating to the Arizona health care cost containment system.
69	69
70	70
71	71
72	72
73	73
74	74	(TEXT OF BILL BEGINS ON NEXT PAGE)
75	75
76	76
77	77
78	78	Be it enacted by the Legislature of the State of Arizona: Section 1. Title 36, chapter 29, article 1, Arizona Revised Statutes, is amended by adding section 36-2903.14, to read: START_STATUTE36-2903.14. Sickle cell disease; annual review of medications, treatments and services; annual report A. The administration shall conduct an annual review of all medications and forms of treatment for sickle cell disease and services available to members with a diagnosis of sickle cell disease that are eligible for coverage under this article. The purpose of the annual review is to determine whether the available covered medications, treatments and services are adequate to meet the needs of members with a diagnosis of sickle cell disease and whether the administration should seek to add additional medications, treatments or services. B. When conducting the annual review required by this section, the administration shall solicit and consider input from the general public, with specific emphasis on attempting to receive input from persons or groups with knowledge and experience in the area of sickle cell disease treatment. C. On or before January 15, 2024, and on or before January 15 each year thereafter, the administration shall submit a report to the governor, the speaker of the house of representatives, the president of the senate and the health and human services committees of the house of representative and senate, or their successor committees, and shall provide a copy of the report to the secretary of state. The report shall detail the administration's findings from the annual review required by this section, as well as any recommendations based on those findings. The administration shall post the annual report required by this section on its public website. END_STATUTE
79	79
80	80	Be it enacted by the Legislature of the State of Arizona:
81	81
82	82	Section 1. Title 36, chapter 29, article 1, Arizona Revised Statutes, is amended by adding section 36-2903.14, to read:
83	83
84	84	START_STATUTE36-2903.14. Sickle cell disease; annual review of medications, treatments and services; annual report
85	85
86	86	A. The administration shall conduct an annual review of all medications and forms of treatment for sickle cell disease and services available to members with a diagnosis of sickle cell disease that are eligible for coverage under this article. The purpose of the annual review is to determine whether the available covered medications, treatments and services are adequate to meet the needs of members with a diagnosis of sickle cell disease and whether the administration should seek to add additional medications, treatments or services.
87	87
88	88	B. When conducting the annual review required by this section, the administration shall solicit and consider input from the general public, with specific emphasis on attempting to receive input from persons or groups with knowledge and experience in the area of sickle cell disease treatment.
89	89
90	90	C. On or before January 15, 2024, and on or before January 15 each year thereafter, the administration shall submit a report to the governor, the speaker of the house of representatives, the president of the senate and the health and human services committees of the house of representative and senate, or their successor committees, and shall provide a copy of the report to the secretary of state. The report shall detail the administration's findings from the annual review required by this section, as well as any recommendations based on those findings. The administration shall post the annual report required by this section on its public website. END_STATUTE